Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Loncastuximab Tesirine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ADC touts early Zynlonta results in marginal zone lymphoma
    ADC touts early Zynlonta results in marginal zone lymphoma

    07 May 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/adc-therapeutics-touts-early-zynlonta-results-marginal-zone-lymphoma-raises-105m-through

    FIERCE PHARMA
    07 May 2024
    Share Share
    ADC Reports Q1 2024 Results, Provides Business Update
    ADC Reports Q1 2024 Results, Provides Business Update

    06 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/06/2875646/0/en/ADC-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Updates.html

    GLOBENEWSWIRE
    06 May 2024
    Share Share
    ADC Reports ZYNLONTA® Phase 2 Data In Marginal Zone Lymphoma
    ADC Reports ZYNLONTA® Phase 2 Data In Marginal Zone Lymphoma

    06 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/06/2875641/0/en/ADC-Therapeutics-Announces-Initial-Data-from-Investigator-Initiated-Phase-2-Clinical-Trial-of-ZYNLONTA-in-Patients-with-Relapsed-Refractory-Marginal-Zone-Lymphoma.html

    GLOBENEWSWIRE
    06 May 2024
    Share Share
    Overland ADCT Announces NMPA Accepts BLA & Grants Priority Review for ZYNLONTA
    Overland ADCT Announces NMPA Accepts BLA & Grants Priority Review for ZYNLONTA

    24 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/24/2709420/0/en/Overland-ADCT-BioPharma-Announces-NMPA-Accepts-Biologics-License-Application-and-Grants-Priority-Review-for-ZYNLONTA-for-Treatment-of-Relapsed-or-Refractory-Diffuse-Large-B-cell-Ly.html

    GLOBENEWSWIRE
    24 Jul 2023
    Share Share
    After seven deaths, ADC gets partial hold and decides to stop Zynlonta trial
    After seven deaths, ADC gets partial hold and decides to stop Zynlonta trial

    22 Jul 2023

    // Zoey Becker FIERCE PHARMA

    https://www.fiercepharma.com/pharma/adc-therapeutics-pulls-plug-zynlonta-study-after-fda-partial-hold#:~:text=ADC%20Therapeutics%20pulls%20the%20plug%20on%20Zynlonta%20study%20after%20partial%20FDA%20hold,-By%20Zoey%20Becker&text=A%20week%20after%20ADC%20Therapeutics,an%20FDA%20partial%20clinical%20hold.

    Zoey Becker FIERCE PHARMA
    22 Jul 2023
    Share Share
    ADC Therapeutics pauses enrollment in cancer drug trial after patient deaths
    ADC Therapeutics pauses enrollment in cancer drug trial after patient deaths

    12 Jul 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/adc-therapeutics-pauses-enrolment-mid-stage-trial-cancer-therapy-2023-07-11/

    REUTERS
    12 Jul 2023
    Share Share